Derek Matteo, former Vice President of Global Technology Commercialization at NuVasive, Inc., has joined Dublin, Ireland-based Mainstay Medical Holdings as Vice President of U.S. Sales. Since 2008, Derek has led Global Marketing and Global Commercial Development teams in the orthopedic and spine spaces.
Derek Matteo: New VP of Marketing at Mainstay Medical
1 min read Premium comments
Secondary#mainstaymedical#derekmatteo
Mainstay, which has has subsidiaries operating in Ireland, the U.S., Australia, Germany and the Netherlands, focuses its efforts on commercializing an implantable restorative neurostimulation system—ReActiv8—for people with mechanical chronic low back pain.
Derek Matteo told OTW, “The team at Mainstay has built an incredible foundation of strong clinical data and research supporting the mechanism of action. I look forward to partnering with physicians to deliver clinical education programs to help them deliver this great therapy to their patients.”
“Derek’s experience in product commercialization is just what we need; he understands how to assemble clinical education and training, all supported by a marketing program that informs the physicians community of the clinical value of ReActiv8,” said company CEO Jason Hannon to OTW.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.